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Abstract 
Background: Insulin resistance is a hallmark of type 2 diabetes mellitus (T2DM) and the underlying cause of various 
metabolic changes observed in type 2 diabetic patients. This study investigated the molecular basis of the anti-
hyperglycemic activity of the lanosteryl triterpene (RA-3), from Protorhus longifolia stem bark, in hyperlipidemic and 
streptozotocin (STZ)-induced T2DM in rats.
Methods: The high-fat diet fed (HFD) and STZ-induced T2DM in rat model was used to evaluate the anti-hyperglyce-
mic activity of RA-3. The hyperlipidemic rats received a single intraperitoneal injection of STZ (35 mg/kg body weight) 
to induce T2DM. The experimental animals received a daily oral single dose of RA-3 (100 mg/kg body) for a period 
of 28 days, whiles the control group received distilled water only. The animals were euthanized, and skeletal muscle 
was collected for protein (IRS-1, AKT, GSK and GLUT 4) expression analysis. Western blot confirmed expression of the 
proteins.
Results: Treatment of the diabetic animals with the RA-3 showed marked reduction in fasting plasma glucose levels 
in comparison to the untreated diabetic group animals. A significant decrease in p-GSK-3β and p-AKT expression was 
observed, whereas the expression of IRS-1ser307 were increased when compared to the diabetic control group. This 
effect was ablated upon treatment with RA-3 and this was concomitant to an observed increase in GLUT 4 expression.
Conclusions: The results obtained in the present study strongly suggested that the anti-hyperglycemic effect of RA-3 
could partly be associated with its ability to improve cellular glucose uptake in muscle tissue from T2DM.
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Introduction
The use of medicinal plants and their derived bioactive 
compounds to cure various ailments, including meta-
bolic disorders, has been a preference since the earli-
est of times. There is still a continuous rising interest in 
the use of medicinal plants either in their crude or pure 
form to fight diseases such as diabetes mellitus (DM). 
Triterpenes, a unique class of plant-derived chemicals 
containing three terpene units, have recently gained 
much interest as new targets towards development of 
new pharmacologically active drugs. This is due to their 
wide range of significant biological activities including 
anti-diabetic properties [1–3]. Their hypoglycemic effect 
has been associated with their ability to decrease intesti-
nal glucose absorption [4] and stimulate insulin secretion 
and cellular glucose uptake in peripheral tissues [5]. Sev-
eral in  vitro and in  vivo studies have demonstrated the 
potential of natural triterpenoids to enhance the insulin 
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islets [2, 6, 7]. This class of compounds is also known for 
its inhibitory activity against alpha glucosidase and alpha 
amylase [8], inhibition of protein tyrosine phosphatase 
1B and inhibition of glycogen phosphorylase [9]. Triter-
penes have also demonstrated a strong potential for the 
treatment of DM associated complications such as car-
diomyopathy [10] and beta cell dysfunction [3].
Experimental data in our laboratory have demon-
strated that RA-3, a lanosteryl triterpene from Pro-
torhus longifolia (Benrh.) Engl. (Anacardiaceae) stem 
bark, possesses cardioprotective effect [11], anti-hyper-
lipidaemic [12], and anti-hyperglycaemic activities [13]. 
This compound has been reported to improve glycemic 
control and pancreatic beta cell ultrastructure in HFD-
STZ-induced type 2 diabetic animals [14]. However, the 
molecular mechanism(s) through which the compound 
improves the glucose tolerance in the type 2 diabetic 
animals remains to be explored. Therefore, this study is 
aimed at evaluating the molecular mechanism by which 
RA-3 improves glucose tolerance in the hyperlipidemic 
and STZ-induced type 2 diabetic rats.
Materials and methods
The lanosteryl triterpene extraction and isolation
The fresh stem bark of Protorhus longifolia (specimen 
voucher number RAUZ01) was collected from KwaZulu-
Natal, SA and routinely prepared for extraction. The iso-
lation of the RA-3 was performed from the chloroform 
extract of the powered stem bark of Protorhus longifolia 
using chromatographic techniques as previously reported 
[11–14].
Animals
Sprague–Dawely rats (150–200  g) of either sex were 
provided by the departmental animal unit of Biochem-
istry and Microbiology, University of Zululand. Rats 
were housed and maintained under standard conditions 
[12-h light/dark cycle, humidity (~ 50%), temperature 
(23–25 °C)]. Before commencement of experimental pro-
cedures, the rats were acclimatized for a period of 5 days 
with free access to water and pelleted rat feed. The Uni-
versity of Zululand Research Ethics Committee (UZREC) 
granted the approval for procedures and use of labora-
tory animals (Rattus norvegicus) (UZREC 171110–030 
PGM 2016/329).
Induction of hyperlipidemia
The induction method of hyperlipidemia in rats was per-
formed with some modification as previously described 
by Machaba et al. [12, 14]. The animals in the experimen-
tal group were placed on HFD for 28  days. The blood 
cholesterol levels were measured using ACC UTR END 
 PLUS® cholesterol strips (Roche Products) from the rat’s 
tail tip to confirm the hyperlipidemic state. Blood cho-
lesterol levels above or equal to 5.2  mmol/L were used 
to confirm the hyperlipidemic state of the animals to be 
used in the study.
Type 2 diabetes induction
The hyperlipidemic rats were fasted overnight and then 
intraperitoneally injected with a freshly prepared low 
dose of STZ solution (35  mg/kg) to induce diabetes 
(T2DM) [15, 16]. The blood glucose levels were meas-
ured after 5  days using a glucometer (ACC UTR END 
 PLUS® glucose strips, Roche Products) from the rat’s tail tip 
to confirm the hyperglycemic state of the animals. Blood 
glucose levels above or equal to 11 mmol/L were used to 
confirm the diabetic state of the animals to be used in the 
study [17].
In vivo anti‑hyperglycemic activity
The hypoglycemic activity of RA-3 was assessed in the 
type 2 diabetic animals following the method done by 
Kumar et al. [14, 18]. Animals were randomized into four 
groups (n = 5), fed either a standard rodent diet, while the 
HFD-diabetic (HFD-D) groups received either 2% Tween 
20 (vehicle control), a single dose of RA-3 (100 mg/kg) or 
metformin (100 mg/kg) orally for 28 days. The non-dia-
betic group received equivalent amount of distilled water. 
The animals were allowed free access to water and pel-
leted rat feed throughout the experimental period. Blood 
glucose levels were determined weekly. After 28  days, 
animals were overnight fasted and euthanized and skel-
etal muscles tissue harvested for western blot analysis.
Western blot analysis of some proteins involved in insulin 
signaling pathway
The frozen skeletal muscle was weighed, defrosted on 
ice and lysed in lysis buffer (800 μL) (Pierce Biotech-
nologies, Rockford, CA, USA) using a tissue lyser at 25 
Hz. Thereafter, the samples were centrifuged for 20 min 
at 12,000  rpm at 4  °C in a micro centrifuge. The super-
natant was collected and kept in a fresh tube at − 20 °C 
until required. Protein (30 µg) was mixed with an equal 
volume of 2× Laemmli sample buffer (containing 
β-mercaptoethanol), before it was denatured at 95  °C. 
The denatured protein sample (30  µg) was loaded onto 
a 12% Mini-protein TGX Precast Gels, 10 well comb, 
50 µL/well (BioRad), along with 12 µL BioRad-Western C 
molecular weight marker. The gel was run for 1 h at 150 V 
in Tris/Glycine/SDS-PAGE Buffer 1× and then trans-
ferred to a polyvinylidene fluoride membrane (PVDF, 
Bio-Rad, Hercules, CA, USA) [19]. Membranes were 
incubated at 4  °C for 16  h with different primary anti-
bodies which include IRS-1Ser307, p-AKT and p-GSK-β, 
[Cell Signaling Technology, Danvers, MA, USA; (1:500), 
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(1:1000), (1:1000) respectively], GLUT 4 [Sigma-Aldrich 
Chemical Co., St. Louis, MO, USA, (1:1000)]. β-Actin 
[Cell Signaling Technology, Danvers, MA, USA, (1:4000)] 
antibody was added as a loading control. The membrane 
was incubated with an appropriate horseradish peroxi-
dase conjugated secondary antibody (1:4000) in blocking 
buffer (2.5% milk) at room temperature for 90 min, and 
then placed on a plastic sheet and 2 ml chemiluminescent 
substrate (1:1 of luminal solution and reaction buffer) 
was added to the membrane for signal development. The 
proteins were detected using BioRad ChemiDoc and the 
signaling intensity of the bands was quantified using the 
image J software.
Results
RA‑3 effect on blood glucose in the HFD‑STZ‑induced type 
2 diabetic animals
Figure  1 shows the biological activity of RA-3 on fast-
ing blood glucose (FBG) levels of the type 2 diabetic rats. 
While a persistently higher fasting plasma level of glucose 
was observed in the diabetic control group, treatment of 
the diabetic animals with RA-3 effectively lowered their 
blood glucose levels. The observed effects were similar 
and comparable to those of the metformin treated group.
Effect of RA‑3 on some insulin signaling proteins 
(p‑GSK‑3β, p‑AKT, IRS‑1ser307 and GLUT 4)
Figure  2 shows the findings of the activity of RA-3 on 
some insulin signaling proteins. A relatively low expres-
sion of p-GSK-3β, p-AKT and GLUT 4 along with higher 
expression of IRS-1ser307 was observed in the diabetic 
control group vs non-diabetic control group. However, 
following treatment of the diabetic animals with RA-3, 
higher expression of p-GSK-3β, p-AKT and GLUT 4 and 
lower expression of IRS-1ser307 were observed in com-
parison with the untreated diabetic group. The observed 
effects were similar and comparable to the metformin 
treated group.
Discussion
Experimental evidence has shown that oxidative stress 
and increase in pro-inflammatory cytokines is closely 
related to insulin resistance, through their negative activ-
ity on insulin signaling pathways and glucose transport 
into the cell. Thus, their effects have been suggested to 
explain the development of insulin resistance in T2DM 
[20]. RA-3 has recently established to improve glycaemic 
control and pancreatic beta cell ultrastructure in HFD-
STZ-induced type 2 diabetic rats. The pancreatic beta 
cells protective effect of RA-3 has been linked to the abil-
ity to enhance antioxidant status and reduce the release 
of pro-inflammatory cytokines such as IL-6 [14]. How-
ever, the molecular mechanism(s) through which the 
compound improves the glycaemic control in the type 2 
diabetic animals remained to be explored [14]. Thus, the 
current study aimed at evaluating the molecular mecha-
nism through which RA-3 improves glycaemic control in 
the hyperlipidemic and STZ-induced type 2 diabetic ani-
mals. Normally insulin stimulates cellular glucose uptake 
by activating a cascade of reactions leading to plasma 
membrane recruitment of glucose transporters GLUTs. 
The translocation of these GLUTs is regulated by a series 
of proteins such as PI3-K, AKT and IRS-1. However, 
while PI3-K and AKT are known to be downregulated in 
T2DM, IRS-1Ser307 is known to be highly expressed inhib-
iting insulin signalling pathway and glucose uptake [21].
Interestingly, the results from this study demon-
strated that RA-3 was able to stimulate the insulin 
signaling pathway by reducing the expression of IRS-
1Ser307 and increased p-AKT/p-GSK-3β expression 
after 28 days of treatment. These findings were further 
evidenced by the increased GLUT 4 expression and the 
subsequent anti-hyperglycemic effect indicated by an 
effective reduction of the FBG levels. Phosphorylated 
GSK-3β at ser9 by AKT is well-known to play a major 
role in insulin-induced stimulation of glycogen syn-
thesis. The ability of RA-3 to increase the expression 
of p-GSK-3β shows the potential of this compound to 
control glucose homeostasis by maintaining the bal-
ance between glucose storage and glycogen break-
down, while preventing chronic gluconeogenesis. The 
results obtained from this study provides the molecu-
lar basis through which RA-3 improves glucose toler-
ance in HFD-STZ-induced type 2 diabetic animals, 
which has recently been established in our laboratory 
[14]. The results are also similar and consistent with 
those observed in the type 1 diabetes model reported 
by Mabhida et  al. [22]. The results from this study 
could also partly serve to explain the stimulatory effect 
Fig. 1 The activity of RA-3 on FBG after the 28 days treatment of the 
type 2 diabetic animals. Values are expressed as the mean ± SEM 
(n = 5). ***p ≤ 0.001, vs. non-diabetic control. D diabetic
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of RA-3 on glucose uptake by C2C12 myocytes and 
3T3-L1 adipocytes previously reported by Mosa et al. 
[23]. Oleanolic acid has also been reported to exert its 
hypoglycemic effects through activation of the insulin 
signaling pathway in skeletal muscle of STZ-induced 
diabetic rats [2].
Conclusion
The findings obtained in the present study confirm that 
the hypoglycemic activity of RA-3 is through its appar-
ent ability to enhance the insulin signaling pathway and 
consequently increase the expression of GLUTs in the skel-
etal muscles of diabetic animals. These findings suggest 
that RA-3 could be a potent therapeutic candidate in the 
development of new anti-diabetic drugs. However, further 
molecular studies in which RA-3 regulates the function-
ing of pancreatic beta cells and other related organs are still 
required.
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